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ABSTRACT  1 
This study is based on the heterogeneous nucleation of active pharmaceutical ingredients (APIs) 2 
in the presence of various excipients widely used in the pharmaceutical industry. Carbamazepine 3 
(CBMZ) was successfully crystallized in the presence of the following heterosurfaces: α/β-4 
Lactose, β-D-Mannitol, microcrystalline cellulose and carboxymethyl cellulose. The successful 5 
crystallization of CBMZ FIII in the presence of all the excipients was confirmed by powder X-6 
ray diffraction and scanning electron microscopy, while CBMZ crystals apposition was 7 
confirmed using in-situ SEM-Raman. A pronounced improvement in the dissolution of CBMZ 8 
FIII was observed when crystallized in the presence of excipients when compared with CBMZ 9 
FIII recrystallized using same conditions in the absence of the excipients. The isolated solids 10 
could be simply tabletted by direction compression upon mixing with the desired amount of 11 
disintegrant and lubricant. Hence employing this process could potentially streamline the 12 
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1. INTRODUCTION 1 
Due to the ease of administration and increased compliance of patients to oral medicines they are 2 
the preferred dosage form for the administration of drugs. However, the poor water solubility of 3 
nearly 40% of all active pharmaceutical ingredients (APIs) poses a serious challenge in new drug 4 
development.1 Many drug candidates or developed APIs are classified as Class II in the 5 
Biopharmaceutics Classification System (BCS) because they exhibit high permeability but low 6 
solubility.2 Although limited by low equilibrium solubilities, any enhancement in their 7 
dissolution rates can result in greatly improved bioavailability. Approaches to enhance the 8 
dissolution rate of these poorly soluble drugs include a reduction in particle size, metastable 9 
polymorph selection, salt formation, their application as co-crystals, and their application as 10 
amorphous APIs.3  11 
Various approaches exist for the reduction of particle size and are broadly classified based on 12 
their processing principle, namely, either the ‘top down’ approach or the ‘bottom up’ approach.4 13 
The ‘top down’ approach for particle size reduction involves mechanical processes such as 14 
media milling,5 microfluidization6 and high pressure homogenization.7 However, these 15 
techniques involve high energy input and are inefficient, and at times the final suspensions 16 
incorporate impurities from unavoidable milling abrasion.8 These flaws of ‘top down’ techniques 17 
could be potentially overcome by employing ‘bottom up’ approaches involving crystallization 18 
from solution. The latter involves techniques such as spray drying, 9 antisolvent precipitation,10, 19 
11 the use of supercritical fluids (SCF),12, 13 sonoprecipitation,14 crystallization from 20 
microemulsions,15 solids dispersion,16 inclusion complexes17 and crystallization in confined 21 
volumes.18, 19 22 
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Significant progress has been reported in using solid particles or heterosurfaces as nucleation or 1 
crystallization mediators, particularly in the field of pharmaceuticals.20, 21 The presence of such 2 
substrates generally decreases the free energy barrier for nucleation, which enhances the rate of 3 
nucleation resulting in  smaller particle sizes at a particular supersaturation level.22 The main 4 
factors postulated to influence the interfacial energy include two-dimensional lattice matching, 23 5 
ledge-directed epitaxy,22 functional group interactions,24 and monolayer formation.25 In addition, 6 
heterogeneous nucleation has been demonstrated on polymers26  and on metallic surfaces.26, 27 7 
This work has shown the capacity to control polymorph selection26 and purity27 by attachment of 8 
APIs to heterosurfaces. Poornachary et al.28 effectively crystallized micronized particles of 9 
naproxen (BCS Class II) using an antisolvent precipitation method aided by polymeric additives 10 
such as polyvinylpyrrolidone (PVP) resulting in enhanced dissolution rates and absorption 11 
efficiency. Eral et al.18 successfully crystallized hydrophobic and hydrophilic APIs, fenofibrate 12 
and acetaminophen respectively, by encapsulation in biocompatible alginates thereby controlling 13 
their dissolution rates. Zhang et al.29 improved the oral bioavailability and drug permeability of 14 
telmisartan (TEL) by successfully crystallizing it within spherical mesoporous silica 15 
nanoparticles. Hence, molecular recognition of different APIs at various interfaces has been well 16 
recognized to control their nucleation and growth, thereby leading to improved dissolution 17 
rates.30  18 
Excipients are the pharmaceutically inactive components in medicinal products which enhance 19 
processability and product performance by enabling efficient formulation and safer medication.31 20 
All pharmaceutical dosage forms contain excipients. Excipients typically have multiple functions 21 
within the formulation of a tablet. For example, sugar-based excipients such as lactose and 22 
mannitol are used commonly used as diluents and compression aids. Polymeric excipients such 23 
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as cellulose derivatives also have wide applicability in tablet formulations; microcrystalline 1 
cellulose is widely used as a diluent, disintegrant, compression aid and lubricant and 2 
carboxymethyl cellulose is employed as a binding agent and disintegrant.32   3 
The present work focuses on the crystallization of an API in the presence of four different 4 
excipient heterosurfaces and the resultant dissolution rates of the final API-excipient composites. 5 
The excipients chosen for this work were α/β-Lactose (α/β-Lac), β-D-Mannitol (β-D-Man), 6 
microcrystalline cellulose (MCC) and carboxymethyl cellulose (CMC), as they are widely used 7 
in the pharmaceutical industry and are approved by the US Food and Drug Administration 8 
(FDA). The former two are crystalline excipients while the latter two are semi-crystalline or 9 
amorphous. The study was based on the hypothesises that (a) nucleation rate of the API would be 10 
enhanced upon crystallisation in the presence of excipients, (b) smaller particles of API would 11 
crystallise as a result of enhanced nucleation, favouring faster dissolution rates and (c) the API-12 
excipient composite would have improved process properties such as tableting due to the 13 
uniform composite powder. This could potentially dispense with milling and granulation 14 
processes during formulation of the API with an excipient into a tablet dosage form. The 15 
heterogeneous crystallization process was also scaled up to a batch 600 mL scale using a 16 
LabMax® crystallizer equipped with in situ Fourier Transform Infrared (FTIR) probe; confirming 17 
the stress-free scalability of the process.  18 
The model drug used for this work is Carbamazepine (CBMZ). It is a well-established 19 
anticonvulsant drug applied to treat epilepsy and trigeminal neuralgia. It is generally 20 
administered orally and has high intestinal permeability but poor solubility in water. It, therefore, 21 
exhibits irregular absorption in the body and is classified as a BCS Class II drug.33  CBMZ 22 
exhibits five polymorphic forms (I, II, III, IV and V), a dihydrate and several other solvates, such 23 
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as CBMZ-monoacetonate.34, 35 CBMZ FIII is the commercially available form, while CBMZ 1 
dihydrate is the thermodynamically stable form and thus displays the lowest solubility in an 2 
aqueous environment; all polymorphs transform to the dihydrate via solution mediated phase 3 
transformations (SMPT).36, 37  Several attempts to improve the dissolution rate of CBMZ via 4 
micronization of its particles are already reported in the literature. 38, 39 Kumar et al.39 reported a 5 
significant increase in the dissolution rate of CBMZ relative to that observed for the ‘as received’ 6 
material following the successful preparation and stabilization of CBMZ nanoparticles (< 50 nm) 7 
via antisolvent precipitation in the presence of PVP. Furthermore, an enhanced CBMZ 8 
dissolution rate was realized following its confined crystallization within mesoporous silicate 9 
(MCM-41).40 A significant amount of work has also been reported in the literature comparing the 10 
improved dissolution rates of different formulations of commercially available CBMZ samples.41  11 
The goal of this work is to heterogeneously crystallize CBMZ in the presence of α/β-Lac, β-D-12 
Man, MCC and CMC and control the crystal size of CBMZ crystal during the process, to 13 
improve the flow and compaction properties of CBMZ for direct compression tableting and also 14 
to increase the dissolution rate of CBMZ. 15 
2. EXPERIMENTAL SECTION 16 
2.1. Materials 17 
Methanol (MeOH, >99.9 %), β-D-Mannitol (β-D-Man) (D50: 250 µm), α/β-Lactose (α/β-Lac) 18 
(≤30% α-anomer; ≥99% total lactose, D50: 100 µm) and phosphate buffer saline (PBS) tablets 19 
(pH = 7.4) were supplied by Sigma-Aldrich and used as-received. Microcrystalline cellulose 20 
(MCC) (MW:  36000 g/mol, D50: 100 µm) was supplied by Avicel Biopharm and 21 
carboxymethyl cellulose sodium salt (CMC) (MW: 1-2 Χ 105 g/mol, D50: 100 µm) was supplied 22 
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by Merck; both were used as-received. Carbamazepine (CBMZ, >98%) was supplied by Novartis 1 
and used as-received (Figure 1). The powder X-ray diffraction (PXRD) of the as-received CBMZ 2 
confirmed it to be monoclinic-C Form III (CCDC CBMZPN10). 3 
 4 
Figure 1. Molecular structure of CBMZ and the excipients  5 
2.2. Solubility of CBMZ and excipients in MeOH 6 
For the purposes of this study, the solubility data for CBMZ in MeOH previously reported by 7 
O’Mahony et al.42 were used. The solubility of the four excipients in MeOH at 25 ˚C was 8 
measured according to the procedure of Arribas Bueno et al.,43 with each solubility measurement 9 
being performed in triplicate.   10 
2.3. Determination of the induction time for CBMZ in MeOH in the absence of 11 
excipients 12 
A stock solution of CBMZ (34.7 g) in MeOH (450 mL) saturated at 25 ˚C was prepared using 13 
the solubility data of O’Mahony et al.42 in a sealed 500 mL Duran flask. The solution was 14 
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agitated with a PTFE stirrer at 300 rpm and allowed to equilibrate at 5 ˚C above the saturation 1 
temperature for 24 h to ensure complete dissolution. Twenty glass vials were each filled with 20 2 
mL of stock solution via preheated syringes and 0.2 µm nylon filters. These solutions were 3 
agitated with PTFE stirrers at 300 rpm and allowed to equilibrate at 5 ˚C above the saturation 4 
temperature for 24 h. All vials were then transferred to a water bath equilibrated at the desired 5 
crystallization temperature of 18, 15 or 10 ˚C. With reference to the reported solubility data for 6 
CBMZ, these crystallization temperatures corresponded to supersaturations of 1.22, 1.34, and 7 







c = the supersaturated concentration of CBMZ FIII in MeOH in grams of CBMZ FIII / kg of 10 
MeOH 11 
c* = the equilibrium concentration of CBMZ FIII at the crystallization temperature in grams of 12 
CBMZ FIII / kg of MeOH 13 
The induction time of each vial (defined as the time when the first crystals of CBMZ were 14 
observed to crystallize in the first vial) was measured using a webcam (Microsoft life cam, wide 15 
angle f/2.2, HD lens 720 p HD, 30 fps, autofocus widescreen). Induction time experiments were 16 
performed at least three times at each crystallization temperature to ensure sufficient data points 17 
for the corresponding distributions.  18 
2.4. Determination of the Metastable Zone Width for a solution of CBMZ in MeOH 19 
saturated at 25 ˚C  20 
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The metastable zone width (MSZW) of a CBMZ-MeOH solution saturated at 25 ˚C was 1 
specifically determined because all crystallization experiments in this study were performed at 2 
this saturation level. Twenty glass vials were each filled with 20 mL of stock solution, saturated 3 
at 25 ˚C, as described in section 2.3. Thereafter, all vials were cooled to 5 ˚C at a cooling rate of 4 
0.25 ˚C/min and the onset of crystallization (defined as the temperature at which the first crystals 5 
of CBMZ were observed to crystallize in the first vial) was recorded using a webcam as before. 6 
The cooling crystallization was performed three times and the average temperature for the onset 7 
of crystallization was used to determine the MSZW.  8 
2.5. Crystallization of CBMZ from MeOH in the presence and absence of excipients: 20 9 
mL scale 10 
A stock solution (150 mL) of CBMZ in MeOH saturated at 25 ˚C was prepared in a sealed 250 11 
mL Duran flask.42 The solution was agitated with a PTFE stirrer at 300 rpm and equilibrated at 5 12 
˚C above the saturation temperature for 24 h to ensure complete dissolution. Seven glass vials 13 
were each filled with 20 mL aliquots of stock solution via preheated syringes and 0.2 µm nylon 14 
filters. The contents of each vial were agitated with a PTFE stirrer at 300 rpm and equilibrated at 15 
5 ˚C above the saturation temperature for 24 h to ensure complete dissolution. Dry excipient 16 
(either β-D-Man, α/β-Lac, MCC or CMC) was added to each vial and the vials were then 17 
immediately transferred to water baths set at 18, 15 or 10 ˚C. The resultant suspensions were 18 
agitated with PTFE stirrers at 600 rpm and, at defined ‘contact time’ intervals (0h, 1h, 2h, 2.5h, 19 
3h, 3.5h and 4h), vials were removed from the water bath and the solids allowed to settle at room 20 
temperature for 2 min. Two mL of the supernatant were then withdrawn from each vial and 21 
filtered into clean pre-weighed vials using preheated (Tsat + 5 ˚C) and 0.2 µm PTFE filter. The 22 
solvent was evaporated from each vial at room temperature in a ventilated laboratory hood, and 23 
Page 9 of 43
ACS Paragon Plus Environment






























































the vials were then transferred to an oven at 40 °C until a constant weight was achieved; the 1 
visual appearance of the resultant composite solid samples was monitored during drying. 2 
Thereafter, the corresponding solution concentrations of CBMZ in grams per kg of MeOH were 3 
determined gravimetrically according to the procedure of Granberg et al.44 The amount of 4 
excipient added to each vial was such that a maximum attainable CBMZ loading of 25% w/w 5 
would be achieved assuming complete desupersaturation of the CBMZ-MeOH metastable 6 












The above procedure was also performed in the absence of excipients as a control experiment. 8 
The Amounts of excipients added to each vial to attain a maximum loading of 25% w/w at 9 
supersaturations of 1.22, 1.34 and 1.44 was 0.86 g, 1.17 g and 1.65 g respectively. 10 
 11 
2.6. Crystallization of CBMZ from MeOH in the presence and absence of MCC: 600 12 
mL scale 13 
Crystallization of CBMZ in the presence and absence of MCC was performed at a 600 mL scale 14 
in a 1 L LabMax Automated Reactor (Mettler Toledo). Nucleation and %-desupersaturation were 15 
monitored in situ via ATR-FTIR (iC10 (Mettler Toledo)) in conjunction with iControl LabMax 16 
software (Mettler Toledo). The crystallizations proceeded under isothermal conditions following 17 
cooling of saturated solutions of CBMZ in MeOH at 25 °C to a crystallization temperature of 15 18 
°C which generated a supersaturation (S) of 1.34. 19 
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2.7. Characterisation of the supernatant and the isolated CBMZ-excipient composite 1 
solids 2 
2.7.1. Quantification of the amount of CBMZ in the supernatant 3 







csupernatant = Concentration of CBMZ in the supernatant (g CBMZ/kg MeOH) 6 
c = Initial concentration of CBMZ (g CBMZ/kg MeOH) 7 
c
* = Equilibrium concentration of CBMZ at Tcry (g CBMZ/kg MeOH) 8 
2.7.2. Powder X-ray diffraction 9 
Powder X-ray diffractograms (PXRDs) were recorded on a PANalytical diffractometer using a 10 
Cu radiation source (λ=1.541nm) at 40 mA and 40 kV. Scans were performed between 5-35° 2θ 11 
at a scan rate of 0.013° 2θ/min.  12 
2.7.3. Scanning Electron Microscopy  13 
The habit of the isolated particles was examined by SEM (JCM-5700 (JEOL)). Samples were 14 
gold coated (S150B, Edward) and the surface appearance of the as-received α/β-Lac, β-D-Man, 15 
MCC, CMC and the isolated CBMZ-excipient composite solids was compared. 16 
2.7.4. in-situ SEM-Raman spectroscopy 17 
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Micro-Raman measurements were performed on an InVIA Reflex spectrometer (Renishaw) 1 
coupled to an optical microscope (DM2500, Leica) and a SEM (JSM-6510LV, JEOL).  2 
Instrument calibration was performed using the Si (100) peak (520.5 ± 1 cm-1). Spectra were 3 
acquired using the 785 nm laser, variable laser power (0.1 – 10 mW), acquisition times (10 – 500 4 
s) and accumulations (1 – 20) over the spectral range of interest. The spot size of the Raman 5 
laser was 1.5µm. Spectra collection and processing were performed with the WIRETM 4.1 6 
software (Renishaw). 7 
2.8. Particle size distribution (PSD) analysis of CBMZ crystallized in the presence of 8 
excipients 9 
The size of the CBMZ particles crystallized in the presence of the suspended excipients was 10 
measured from the respective SEM micrographs using the ‘measuring’ tool of ‘Adobe Acrobat 11 
Reader DC’. More than 75 particles were measured for each sample. Measured sizes were 12 
plotted as histograms and the data were fitted to normal distributions to obtain the PSD along 13 
with the mean and standard deviation of the crystal sizes. 14 
2.9. Tableting of CBMZ-based solids  15 
Initially, two formulations were prepared by physically mixing CBMZ (as-received) and MCC to 16 
give a CBMZ loading of 25% w/w; this physical mix is known here as ‘PhysMix25’. This first 17 
formulation was a blend of PhysMix25 and magnesium stearate (0.1% w/w) as a lubricant, while 18 
the second formulation comprised a blend of PhysMix25, magnesium stearate (0.1% w/w) and 19 
CMC (5% w/w) as a disintegrant. A further two formulations were prepared using the composite 20 
solids generated via the crystallization of CBMZ in the presence of MCC at 600 mL scale 21 
(LabMax) where the crystallization had been allowed to proceed to full desupersaturation as 22 
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confirmed from the in situ ATR-FTIR measurements – by so doing, this ensured that the actual 1 
CBMZ loading in the composite solid was equal to that of the maximum attainable of 25% w/w 2 
in the comparison experiments. These composite solids are therefore known here as 3 
‘Composite25’. Two tablet blends of Composite25 were prepared; the first was a blend of 4 
Composite25 and magnesium stearate (0.1% w/w), the second a blend of Compsite25, 5 
magnesium stearate (0.1% w/w) and CMC (5% w/w). Components of all CBMZ-based blends, 6 
with the exception of magnesium stearate, were blended in a 3.5 L cubic blender (Erweka, 7 
Germany) at 30 rpm for 30 minutes. Magnesium stearate was then added to respective blends 8 
and blended for a further 1 min at 30 prm. 9 
CBMZ-based blends were gravity fed from the hopper to the die table and compacted into tablets 10 
at 3kN, 6kN, 9kN, 12kN and 15kN using 8 mm round, flat faced punches on a Riva Piccola 11 
tablet press (Riva, Hampshire, United Kingdom). Compression and ejection profiles were 12 
generated using AIM software (Measurement Control Corporation, New Jersey, USA). The 13 
hardness (H), thickness (t), diameter (D) and weight of the tablets produced were determined 14 
using a SMARTTEST50 Autotester (Pharmatron, Switzerland) (n = 20).  The tablet tensile 15 







where  18 
H = Hardness (N) 19 
t = tablet thickness (mm) 20 
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d = tablet diameter (mm)  1 
2.10. In vitro drug release profile studies 2 
In vitro drug release profile studies were undertaken on: (i) powder samples of the CBMZ-3 
excipient composite solids obtained from crystallizations performed at 20 mL scale and a contact 4 
time of 3 h, (ii) tablets containing PhysMix25 with magnesium stearate, and with magnesium 5 
stearate and CMC, (iii) tablets containing Composite25 with magnesium stearate, and with 6 
magnesium stearate and CMC, and (iv) tablets of Tegretol® (100 mg), an approved solid oral 7 
dose formulation of CBMZ marketed by Novartis.  8 
The dissolution of powder samples was performed under sink conditions with a maximum 9 
CBMZ solution concentration, [CBMZ]max, of 40 mg/L (versus the corresponding equilibrium 10 
solubility, [CBMZ]eq, of 162 mg/L) in phosphate buffered saline (PBS) in 500 mL at pH 7.4. The 11 
rotation speed was set to 150 rpm using a magnetic stirrer and the temperature of the dissolution 12 
medium was maintained at 37 ± 1 ̊C. One mL aliquots were withdrawn at predetermined time 13 
intervals (1, 3, 5, 10, 15, 30, 45 and 60 min) and were filtered by Whatman Nylon 13 mm filters 14 
of 0.2 µm pore size before being analysed by UV spectrophotometry. The CBMZ absorption 15 
maximum (λmax = 285 nm) was used to quantify the amount of CBMZ dissolved. 16 
The dissolution of samples of the various tablet formulations of PhysMix25 and Composite25 17 
was carried out using a PHARMATEST PTWS 120D dissolution test system, USP type II 18 
(paddle) apparatus. Dissolutions were performed in 900 mL of 0.1M HCl at 37 ± 1 ̊C at a paddle 19 
rotation of 100 rpm. Again, each experiment was performed under sink conditions whereby a 20 
150 mg composite tablet was placed in the dissolution media, generating a [CBMZ]max  = 37.5 21 
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mg/L versus [CBMZ]eq = 211 mg/L. One mL aliquots were withdrawn at predetermined time 1 
intervals and the amount of CBMZ dissolved was determined via UV as described above.  2 
The dissolution of Tegretol tablets was performed in the same manner as that described above 3 
for tablet formulations of PhysMix25 and Composite25.   4 
3. RESULTS 5 
3.1. Solubility of CBMZ and Excipients in MeOH 6 
The solubility of CBMZ at 25, 18, 15 and 10 ̊C is 97.6, 79.4, 72.7 and 62.7 g/kg MeOH 7 
respectively, as reported by O’Mahony et al.42 In this present study, the corresponding 8 
solubilities of MCC, CMC, α/β-Lac and β-D-Man at 25 ̊C were determined to be 0.08, 0.16, 0.90 9 
and 1.57 g/kg MeOH respectively. As such, the solubilities of all four excipients in MeOH were 10 
deemed negligible compared with that of CBMZ at the working temperature of 25 ̊C used in the 11 
crystallization experiments performed in this study. 12 
3.2. Estimation of the MSZW and determination of the induction time for the 13 
crystallization of CBMZ from MeOH in the absence of excipients 14 
Figure 2 presents the solubility curve for CBMZ (Form III) in MeOH between 5 and 35  ̊C as 15 
reported in the literature.42 It also presents an estimate of the metastable zone limit (dashed red 16 
line) based on an extrapolation through the MSZW data points experimentally determined at the 17 
saturation temperature (Tsat) of interest in this study, 25 °C. As such, a MSZW of 9.5 ̊C was 18 
defined for Tsat = 25 °C at a cooling rate of 0.25 °C/min.  19 
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Figure 2. Literature solubility values42 for CBMZ in MeOH between 5 and 35 °C () plotted 2 
with the estimated MSZ limit (dashed red line) based on an extrapolation through the 3 
experimentally determined MSZW data point () for CBMZ in MeOH from a saturation 4 
temperature (Tsat) of 25 °C and at cooling rate of 0.25 °C/min. Selected saturation data points () 5 
for CBMZ in MeOH at different crystallization temperatures (Tcry) are also indicated. 6 
 7 
Table 1: The mean induction time and the nucleation rate (J) of metastable CBMZ-MeOH 8 
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1.55 35 19.4 
1.34 184 3.7 
1.22 535 1.4 
 1 
To characterize the nucleation behavior of CBMZ from metastable MeOH solutions in the 2 
absence of excipients, the induction time of CBMZ-MeOH metastable solutions saturated at 3 
25  ̊C was determined at crystallization temperatures of 18, 15 and 10 °C. These crystallization 4 
temperatures generated supersaturations of 1.22, 1.34 and 1.55 respectively. Figure 3 presents 5 
the induction time distributions of CBMZ-MeOH metastable solutions saturated at 25 ̊C in the 6 
absence of excipient. Table 1 summarizes the crystallization time for each supersaturation and 7 
the corresponding nucleation rate, J, (m-3 s-1) which was calculated from the slope of the curve 8 
obtained by fitting the induction time data to the Poisson distribution function46 shown below in 9 
Equation 5. 10 
 3() = 1 − exp	(−78(t − :)) (5) 
  11 
where, 12 
J = nucleation rate (m-3 s-1) 13 
V = volume (m3) 14 
t = actual induction time 15 
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tg = estimated induction time 1 
 2 
Figure 3: Induction time distribution for the nucleation of CBMZ from MeOH solutions in the 3 
absence of excipients at S = 1.22 (▲), 1.34 () and 1.55 () (rpm = 300) at various 4 
thermodynamic driving forces for nucleation (RTlnS). Also shown is the Poisson distribution 5 
function fitted to each data set. 6 
3.3. Crystallization of CBMZ from MeOH in the absence and presence of excipients: 20 7 
mL scale and 600 mL scale 8 
Figure 4 presents the % desupersaturation (with respect to CBMZ FIII) of CBMZ-MeOH 9 
solutions (20 mL scale) in the absence and presence of each of the four excipients at 10 
supersaturations of 1.22, 1.34 and 1.55. More than 60% of the solution desupersaturated in the 11 
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presence of all the excipients at all supersaturations after 3h. 1 
 2 
Figure 4. % Desupersaturation (with respect to CBMZ FIII) of CBMZ–MeOH solutions (20 mL 3 
scale) in the absence and presence of various excipients at the supersaturations (S) indicated; 4 
maximum attainable CBMZ loading = 25% w/w, n ≥ 3. 5 
The crystallization of CBMZ from metastable MeOH solutions in the absence and presence of 6 
MCC was also studied at 600 mL scale to assess the scalability of the crystallization process. 7 
Figure 5 illustrates the change in induction time and the rate of desupersaturation in terms of the 8 
solution concentration of CBMZ (via FTIR) in the absence and presence of dispersed MCC at an 9 
isothermal crystallization temperature of 15 ̊C (equivalent to a supersaturation of 1.34). Induction 10 
time of CBMZ-MeOH solution reduced from 100 min to 80 min in the presence of MCC as 11 
compared to no MCC.  12 
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Figure 5: The time evolution of % desupersaturation (via FTIR signal at 1672 cm-1) for the 2 
crystallization of CBMZ from a metastable MeOH solution (600 mL scale) (Tsat = 25 ̊C, Tcry = 3 
15 ̊C, S = 1.34) in the absence and presence of dispersed MCC; maximum attainable CBMZ 4 
loading in the presence of MCC = 25% w/w.  5 
 6 
3.4. Characterization of the isolated CBMZ-excipient composite solids 7 
Figure 6 presents the PXRD patterns of the CBMZ-excipient composite solids isolated at various 8 
time intervals from 0 - 4 h during the crystallization of CBMZ from MeOH solutions in the 9 
presence of the four excipients at a supersaturation of 1.34 (20 mL scale). PXRD confirms 10 
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crystallisation of CBMZ FIII in the presence of all the excipients at all supersaturations. 1 
 2 
Figure 6: PXRD patterns of the composite solids isolated at different time intervals between 0 3 
and 4 h during the crystallization of CMBZ from MeOH solutions in the presence of (a) α/β-Lac 4 
, (b) β-D-Man, (c) MCC, and (d) CMC, at Tsat = 25 ̊C, Tcry = 15 ̊C, S = 1.34. 5 
Figure 7 presents example SEM micrographs of the various composite solids isolated after 3 h 6 
during the crystallization of CBMZ in the presence of the different excipients. They indicate the 7 
presence of block-shaped crystals of CBMZ FIII apposed to excipient particles for all four 8 
excipients. 9 
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Figure 7: SEM micrographs of the isolated composite solids after 3 hours’ contact time with 2 
CMC, MCC, α/β-Lac and β-D-Man during the crystallization of CBMZ from MeOH solutions at 3 
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the supersaturations indicated, and of CBMZ crystallized at the indicated supersaturations in the 1 
absence of excipients. 2 
Figure 8 presents the in-situ SEM-Raman analysis performed on a sample of the composite solid 3 
obtained following the crystallization of CBMZ from MeOH at S=1.34 in the presence of MCC. 4 
In-situ Raman spectra, taken at different locations on the SEM micrograph, confirm the presence 5 
of CBMZ in the composite mixture at spot numbers 2, 3 and 4, and in so doing provide evidence 6 
of the adherence of the CBMZ crystal to the MCC.  7 
 8 
Figure 8: SEM micrograph of a portion of the composite solid obtained following the 9 
crystallization of CBMZ from MeOH (S=1.34) in the presence of MCC. Spot numbers 1 to 4 10 
indicate the regions from where the associated Raman spectra were collected (spectral range 675 11 
– 750 cm-1).  12 
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SEM micrographs were further examined to determine the particle size distribution of CBMZ 1 
crystals recrystallized from MeOH in the absence of excipients, and CBMZ crystals crystallized 2 
from MeOH in the presence of excipients. The corresponding D50 (µm) data are presented in 3 
Table 2.  4 
Table 2: Particle size distribution, D50 (µm), of CBMZ FIII crystals present on the SEM 5 
micrographs of solid samples obtained at different supersaturation levels following (i) the 6 
recrystallization of CBMZ from MeOH in the absence of excipients, and (ii) CBMZ’s 7 
crystallization from MeOH in the presence of excipients – maximum attainable CBMZ loading 8 
in the presence of excipients = 25% w/w.  9 
 10 
Figure 9 presents the dissolution profiles of CBMZ from (i) powder samples of CBMZ 11 
recrystallized from MeOH in the absence of excipients at S = 1.22, 1.34 and 1.55, and (ii) 12 
powder samples of Composite25 produced using each of the four excipients, also at S = 1.22, 13 
1.34 and 1.55. Even though the particle size distributions of the CBMZ crystals were comparable 14 
Supersaturation 
Particle size distribution of CBMZ FIII crystals, D50 (µm) 
Excipient 
None α/β-Lac β-D-Man MCC CMC 
1.22 22 ± 10 16 ± 11 13 ± 14 17 ± 11 13 ± 7 
1.34 23 ± 10 23 ± 14 13 ± 7 14 ± 7 32 ± 22 
1.55 27 ± 12 17 ± 9 18 ± 10 19 ± 10 20 ± 10 
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for both sets of samples tested, the CBMZ crystals present within all Composite25 samples 1 
dissolved at a faster rate than the crystals of recrystallized CBMZ.  2 
 3 
Figure 9: The dissolution profiles of (i) powder samples of CBMZ recrystallized from MeOH in 4 
the absence of excipients at S = 1.22, 1.34 and 1.55, and (ii) composite solid powder samples of 5 
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CBMZ crystallized from MeOH (20 m L scale) in presence of CMC, β-D-Man, MCC or α/β-Lac 1 
with a maximum attainable CBMZ loading of 25% w/w (i.e. Composite25) and also at S = 1.22, 2 
1.34 and 1.55. The corresponding CBMZ D50 particle size distribution values are quoted in the 3 
legends. Dissolution conditions: Phosphate Buffer Saline (PBS), pH 7.4, 37 ± 1 ̊C, 150 rpm, 4 
[CBMZ]max = 40 mg/L versus [CBMZ]eq = 162 mg/L. 5 
 6 
Figure 10 presents the dissolution profiles of CBMZ from  (i) a powder sample of Composite25 7 
using MCC (20 mL scale, S=1.22), (ii) a powder sample of PhysMix25 using MCC, and (iii) a 8 
powdered portion of a 100 mg tablet of Tegretol. Prior to its dissolution, the Tegretol tablet was 9 
gently ground by hand and passed through a 190 µm sieve to give a homogeneous powder with 10 
particles of comparable size to those of the other two powder samples. The amount of Tegretol 11 
powder used equated to the same [CBMZ]max of 40 g/L as was applied to the other two samples. 12 
100% dissolution was achieved for all samples after 12 h. 13 
 14 
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Figure 10: The dissolution profiles of CBMZ from the following CBMZ-based powder samples: 2 
(i) Composite25 using MCC (20 mL scale, S=1.22), (ii) PhysMix25 using MCC, and (iii) a 3 
portion of powder from a hand-ground tablet (100mg) of Tegretol. Dissolution conditions: 4 
Phosphate Buffered Saline (PBS), pH 7.4, 37 ± 1 ̊C, 150 rpm, [CBMZ]max = 40 mg/L versus 5 
[CBMZ]eq = 162 mg/L. 6 
 7 
Figure 11 compares the tensile strength (MPa) versus compression force (MPa) curve for the 8 
CBMZ-based tablets made from (i) Composite25 using MCC (600 mL scale, S=1.34), and (ii) 9 
PhysMix25 using MCC. All tablets also contained 0.1% w/w of magnesium stearate as a 10 
lubricant. 11 












 Powder sample - Tegretol tablet
 Powder sample - PhyMix25 using MCC 
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Figure 11: The variation in tensile strength observed versus the compression force applied to the 2 
following two types of CBMZ-based tablet formulations: (i) Composite25 using MCC (600 mL 3 
scale, S=1.34), and (ii) PhysMix25 using MCC. Both tablet formulation types contained 0.1% 4 
w/w magnesium stearate lubricant. n = 20, horizontal and vertical error bars indicate standard 5 
deviation. 6 
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Figure 12 illustrates the dissolution profiles of CBMZ in 0.1 M HCl from the following CBMZ-1 
based tablet formulations, all of which used MCC as the excipient. 2 
 3 
Figure 12: Dissolution profiles for the following CBMZ-based formulations: 150 mg tablets of 4 
Composite25 using MCC (600 mL scale, S=1.34) + magnesium stearate (0.1% w/w) + CMC 5 
(5.0% w/w), compressed to 3kN (●) (ii) 150 mg tablets of PhysMix25 using MCC + magnesium 6 
stearate (0.1% w/w) + CMC (5.0% w/w), compressed to 3kN (■) (iii) 150 mg tablets of 7 
Composite25 using MCC (600 mL scale, S=1.34) + magnesium stearate (0.1% w/w), 8 
compressed to 3kN (○) (iv) 150 mg tablets of PhysMix25 using MCC + magnesium stearate 9 
(0.1% w/w), compressed to 3kN (□) (v) powder samples of Composite25 using MCC (600 mL 10 
scale, S=1.34)  (∆), and (vi) a solid tablet portion (i.e. unground) from a 100 mg tablet of 11 
Tegretol (ж). Dissolution conditions: PHARMATEST PTWS 120D dissolution test system, USP 12 
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type II (paddle) apparatus. 900 mL, 0.1M HCl, 37 ± 1 ̊C, 100 rpm, [CBMZ]max = 37.5 mg/L 1 
versus [CBMZ]eq = 211 mg/L, n ≥ 3. 2 
4. DISCUSSION 3 
Crystallization from solution is considered to be the most efficient approach to control crystal 4 
morphology, purity and size distribution.47 Often, unintentionally or intentionally, added surfaces 5 
can promote heterogeneous nucleation during crystallization at laboratory scale.48 Increasing 6 
demand for control of physical properties, especially dissolution, of APIs places emphasis on 7 
control of nucleation and growth so as to get smaller crystal size distributions. In this study, 8 
CBMZ was heterogeneously nucleated and crystallized in the presence of excipients such as α/β-9 
Lactose, β-D-Mannitol, MCC and CMC. Excipients were selected as the heterosurfaces for this 10 
project because of their crucial requirement in the pharmaceutical industry during formulation 11 
steps. Several reports in the literature discuss the requirement of functional group 12 
complementarity between API and heterosurface to induce fast nucleation and crystallize 13 
particular polymorphs of the API.21, 22, 49 CBMZ has an amide functional group (-CONH2) which 14 
is capable of hydrogen bond interaction. Therefore excipients possessing hydroxyl groups (-O-H) 15 
should promote nucleation through preferential interactions with CBMZ nuclei (-O-H---O=C-).  16 
Thus the hypothesis for this work was that crystallisation in the presence of excipient could (i) 17 
improve the efficiency and the robustness of the crystallisation process, e.g. steady 18 
desupersaturation rates, decreased nucleation times and reduced particle growth, and (ii) improve 19 
the process properties, e.g. compactability and tabletting, of the API-excipient composite, and 20 
thus dispense with typically used milling and granulation processes during formulation of an API 21 
with an excipient. 22 
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To confirm the potential heteronucleation zone for CBMZ in methanol, several nucleation 1 
experiments were performed to get an estimate of metastable zone width.50 An average MSZW 2 
of 9.5 ̊C on 20 mL scale was obtained experimentally (Figure 2) and is comparable to that 3 
reported in the literature .51 Guangwen et al.52 have also predicted the MSZW on a scale of 250 4 
mL and 1 L using a HEL crystallizer and FBRM. According to them, the MSZW of CBMZ in 5 
methanol is 14 ̊C and 18 C̊ at 250 mL and 1 L volume respectively. Therefore extrapolating this 6 
data obtains an estimated MSZ of 15.5 ̊C for 600 mL scale. Based on this data, three 7 
supersaturations, 1.22 and 1.34 falling within the MSZW and 1.55 lying outside the MSZW were 8 
selected to examine the influence of heterosurfaces on CBMZ crystallization. Since the 9 
supersaturation of 1.22 and 1.34 lie within the MSZW, homogeneous nucleation will be 10 
suppressed thereby favouring heterogeneous nucleation.  Conversely, heterosurfaces should have 11 
limited effect on CBMZ crystallisation at a supersaturation of 1.55, which lies outside the 12 
MSZW, giving rise to spontaneous homogeneous nucleation. Based on this understanding, 13 
induction time experiments were performed at these supersaturations to get an understanding of 14 
homogeneous nucleation behaviour of CBMZ (Figure 3). Induction time (tind) refers to the time 15 
elapsed for the detection of first few crystals after the attainment of desired supersaturation.53 16 
The average induction times of CBMZ in methanol determined experimentally at 17 
supersaturations of 1.22, 1.34 and 1.55 were 535 min, 184 min and 44 min respectively while the 18 
crystal nucleation rate is 1.4, 3.7 and 19.4 m-3s-1, respectively (Table 1). Higher nucleation rate at 19 
a supersaturation of 1.55 as compared to 1.22 and 1.34 signifies spontaneous nucleation of 20 
CBMZ at 1.55 thereby confirming its position outside the MSZW. 21 
Figure 4 presented the desupersaturation of CBMZ-MeOH metastable solution in the absence 22 
and presence of excipients. Nearly 80% of the solution is desupersaturated in the presence of 23 
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α/β-Lac, CMC and β-D-Man at S of 1.22 and 1.34 while nearly 60% desupersaturation of the 1 
CBMZ-MeOH solution is achieved in the presence of MCC at these respective supersaturations 2 
within 3 h. In comparison to that, only 60% desupersaturation is observed in the absence of 3 
excipients at those supersaturations. Thus, the presence of heterosurfaces in the supersaturated 4 
solution facilitates CBMZ’s crystallization by improving the extent of desupersaturation for a 5 
given contact time. This improvement is not very pronounced for CBMZ and indeed is the 6 
poorest observed to date among a range of APIs presently being studied by our group; in this 7 
regard, the reason for variability in the acceleration of API crystallization in the presence of 8 
heterosurfaces will be addressed in a subsequent publication.  However, their presence appears to 9 
enhance the robustness of the crystallization process in terms of the observed reduced variance in 10 
% desupersaturation levels at the different time intervals, in particular at S = 1.22 and 1.34, in 11 
comparison to the large variance in % desupersaturation in the absence of excipients at same 12 
supersaturations. This signifies a reduction in the stochastic behaviour of the carbamazepine 13 
supersaturated solutions when crystallized in the presence of excipients as compared to their 14 
absence. Stochastic nature implies variability in crystal detection time despite identical 15 
experimental conditions. This type of nucleation behaviour from solution is prominent at a 16 
smaller volume ranging from nanolitre to milliliters, but diminishes as the volume of the solution 17 
increases and is not observed at >200 mL scale. Maggioni and Mazzotti54 have compiled a 18 
detailed list of various crystallizing systems exhibiting stochastic nucleation along with their 19 
working volumes and the method of detection of crystallization. In contrast to the crystallization 20 
behaviour observed at the supersaturation of 1.22 and 1.34, slight or no variability was observed 21 
at a supersaturation of 1.55, also confirming that this supersaturation lies outside the metastable 22 
zone.  It was also observed that polymeric excipients presented decreased variance in % 23 
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desupersaturation as compared to the crystalline excipients. Cellulosic excipients contain a low 1 
level of non-saccharide organic residues originating from lignin, a cross-linked biopolymer, 2 
which is hydrophobic and aromatic in nature.55 This cross-linked residue could potentially 3 
enhance the nucleation behaviour of CBMZ by interacting with the hydrophobic and aromatic 4 
region of CBMZ thereby decreasing the variability in the standard deviation. Variability in 5 
standard deviation decreases further for all the excipients compared to no excipients as the 6 
supersaturation decrease to 1.22 thereby working in the heterogeneous nucleation zone near the 7 
solubility limit. Results from the 20 mL scale were supported by the results obtained from 600 8 
mL scale illustrated in Figure 5. The induction time observed using in-situ FTIR decrease from 9 
110 min in the absence of MCC to 80 min in its presence, thus confirming the heterogeneous 10 
nucleation effect.  11 
PXRD analysis confirms the presence of CBMZ FIII in all the isolated composite powders. All 12 
the isolated composites at various time intervals exhibit the primary peaks of CBMZ FIII 13 
corresponding to (1 0 -1), (1 1 -1) and (0 2 0) faces at 13, 15.2 and 15.9 degrees 2θ as shown in 14 
Figure 6. The peaks associated with CBMZ FIII increase in intensity in a manner consistent with 15 
the desupersaturation profile shown in Figure 4. The block morphology of the CBMZ crystals 16 
observed in the SEM micrographs (Figure 7) also confirms the presence of CBMZ FIII. 17 
Apposition of these block CBMZ crystals to the excipient particles suggests that the 18 
desupersaturation is a consequence of crystal nucleation and growth onto suspended excipient 19 
particles.  These results suggest that a maximum number of crystals were found apposed to the 20 
excipient particles at all the supersaturations but the best adherence was observed in the presence 21 
of cellulose base excipients, MCC and CMC. Polymeric excipients exhibit greater surface 22 
rugosity than the crystalline excipients thereby facilitating enhanced apposition of CBMZ to 23 
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MCC and CMC surfaces. Page and Sear56 clearly demonstrated the effect of different grooves 1 
angles on the surfaces of heterosurfaces change the nucleation behaviour of API solutions.  2 
The particle size distribution of the CBMZ crystals formed in the absence and presence of 3 
excipients was determined using SEM micrographs, Table 2. The micrographs of the 4 
recrystallized CBMZ in the absence of excipient presented crystals with a similar D50 (µm) to 5 
recrystallised CBMZ in the presence of all excipients at different supersaturation levels. The 6 
presence of excipients increases the number of nucleation sites, thus increasing the pre-7 
exponential factor in the classical nucleation theory.  It is the presence of these nucleation sites 8 
on the excipient that promotes nucleation since we are in the metastable zone at the 9 
supersaturations used in this study (1.22 and 1.34). As such different amounts of excipients were 10 
added to ensure that the loading remained constant at 25% w/w; the amount of excipient was 11 
therefore greatest at the highest supersaturation. The presence of a similar number of nucleation 12 
sites at all supersaturations leads to a comparable number of crystals formed thereby leading to 13 
similar particle size distributions for the CBMZ produced; this phenomenon has been previously 14 
observed.43 The attachment of CBMZ FIII to the excipient particles as well as the assignment of 15 
polymorphic form was confirmed by in-situ SEM-Raman. One example of CBMZ attached to 16 
MCC particles is presented in Figure 8. The in-situ SEM-Raman technique helped to visualize 17 
the interfacial interaction between CBMZ and excipient particles and confirms the polymorphic 18 
form of CBMZ as well as distinguishing between CBMZ and excipients particles. Four different 19 
regions were selected on one particular SEM image comprising of CBMZ crystallized in the 20 
presence of MCC. Raman spectrum was collected for each spot in the range from 675 – 750 cm-1 21 
and the peak at 699.1 cm-1 (β(O-H), β(N-H), β(C-H) in carboxamide group) and 724.4 cm-1 (β(O-22 
H), β(N-H) in carboxamide group) were observed for CBMZ FIII presence in the system.57 Spots 23 
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3 and 4 are predominantly CBMZ FIII while spot 2 also exhibits peaks at the same wavenumbers 1 
but with very low intensity as compared to spot 3 &4. Spot 2 is presented as MCC in the SEM 2 
micrograph but weak Raman signals were observed from the same spot potentially due to 3 
multiple reflections of CBMZ signals from other predominant CBMZ surfaces. Raman spectrum 4 
of spot 1 shows no presence of CBMZ FIII suggesting no adsorbed layer of CBMZ onto MCC 5 
surface.  6 
All CBMZ-excipient composites were subjected to dissolution studies. Significant enhancement 7 
in dissolution was observed by crystallizing CBMZ on the heterosurfaces as compared to CBMZ 8 
recrystallized under similar conditions, as illustrated in Figure 9. It is widely accepted that 9 
particle size influences API dissolution rate; smaller particle sizes increase the dissolution rate 10 
and vice versa.58 Despite the different aqueous solubilities of excipient, 100% dissolution is 11 
achieved in all the cases within 60 min. Although crystal size of CBMZ is comparable upon 12 
crystallization in the absence of excipients to the crystals obtained in presence of excipients, 13 
dissolution rate of CBMZ was enhanced following crystallization in the presence of excipients 14 
with 70 -82 % dissolution occurring within 15 mins compared with 42 % for CBMZ 15 
recrystallized in the absence of excipients under the same conditions. The slower dissolution rate 16 
of CBMZ (recrystallised at similar condition) alone is also affected by the conversion of CBMZ 17 
to CBMZ dihydrate which has been meticulously studied and reported in the literature.59 The 18 
dissolution of Composite25 using MCC at a supersaturation of 1.22 is compared with a powder 19 
sample of marketed formulation of CBMZ (Tegretol tablet) and the PhysMix25 using MCC, 20 
Figure 10. Composite25 presented a similar dissolution profile to the PhysMix25 and powdered 21 
Tegretol tablet up to 30 mins and greater dissolution between 30 and 60 min time points. These 22 
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results indicate that crystallising CBMZ in the presence of excipients did not undermine its 1 
dissolution behaviour.  2 
Solids obtained from the 600 mL scale experiment were compressed to different compression 3 
forces to form tablets and also to assess the tableting behaviour of CBMZ crystallized in the 4 
presence of excipients. Low weight variation (< 1 wt%) of the composite tablets compressed at 5 
different compression forces clearly indicates good powder flowability of the composite powder 6 
during gravity feeding of blends from the hopper. CBMZ crystallized in the presence of MCC 7 
was similar to the physical mix of CBMZ and MCC in terms of compaction behaviour as 8 
presented in Figure 11. Hence the heterogeneous crystallization process of CBMZ in the 9 
presence of excipients exhibits no adverse effect on compaction behaviour of CBMZ and MCC.  10 
Tablets (150 mg) made from the solid obtained after the crystallization process i.e. Composite25 11 
and MCC (600 mL scale and S=1.34), PhysMix25 and the marketed CBMZ tablet (Tegretol) 12 
were also subjected to dissolution, Figure 12. Composite25 tablet formulation containing 5% 13 
CMC exhibited a similar dissolution profile compared to the powdered Composite25 and 14 
PhysMix25 tablets with 5% CMC reaching nearly 100% dissolution within 1h. The Composite25 15 
tablets exhibited faster dissolution rate when compared to the marketed CBMZ tablet (Tegretol), 16 
which also contains MCC in major quantity in addition to croscarmellose sodium, CMC sodium, 17 
colloidal silicon dioxide, magnesium stearate and poloxyl 40 stearate as other excipients, 18 
reaching only 40% dissolution in 1 h. Also, Composite25 tablets containing both lubricant and 19 
disintegrant exhibited faster dissolution rate as compared to the Composite25 tablet only 20 
containing lubricant, thereby demonstrating the importance of tablet formulation design to 21 
optimise API dissolution from API-excipient composites. Hence tableting also did not undermine 22 
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the dissolution of Composite25. Therefore, API-excipient composites obtained from this process 1 
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Thus heterogeneous nucleation of a poorly soluble BCS class II API, carbamazepine, in the 2 
presence of excipients, improved the efficiency, by reducing induction times, and the robustness, 3 
by reducing the stochasticity, of the crystallisation process. Dissolution profiles of the API-4 
excipient composite powders and tablets were enhanced compared to the API recrystallized in 5 
the absence of excipient. API-excipient composites produced demonstrated good flow and 6 
compaction properties comparable to a physical mixture of the API and excipient. The intimate 7 
mixtures of micronised API and excipient produced during composite production were 8 
successfully compacted by blending and compression. Therefore the study results demonstrate 9 
the potential of API-excipient composite production to eliminate the need for a milling processes 10 
to reduce API particle size and granulation processes to mininise API segregation thereby 11 
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API, active pharmaceutical ingredient; CBMZ, carbamazepine; PXRD, powder X-ray 2 
diffraction; SEM, scanning electron microscopy; CSD; crystal size distribution; BCS, 3 
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This study is based on the heterogeneous nucleation of carbamazepine (CBMZ) in the presence 8 
of α/β-Lactose, β-D-Mannitol, microcrystalline cellulose and carboxymethyl cellulose. A 9 
pronounced improvement in the dissolution of CBMZ FIII was observed when crystallized in the 10 
presence of excipients. The isolated solids could be simply tabletted by direction compression 11 
upon mixing with the desired amount of disintegrant and lubricant.  12 
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